All lobbying filings

Ferox Strategies

Ferox Strategies filed a Q3 report for Stoke Therapeutics on October 20, 2025, reporting $40,000 in lobbying income.

Lobbying for Stoke Therapeutics · Biotechnology company

As filed: FEROX STRATEGIES for STOKE THERAPEUTICS.

All filings by Ferox Strategies · Everything Stoke Therapeutics has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$40,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 2

MARK WILLIAMS New on this filing

Previously held: Chief of Staff, Rep. Michael Conaway // Chief of Staff, Rep. Todd Rokita // Dep. Chief of Staff/Leg. Director, Rep. Sam Johnson.
MICHAEL TAGGART New on this filing

Previously held: Energy and Commerce Committee --Policy Director; Rep. Cathy McMorris Rodgers -- Legislative Director; Rep. Leonard Lance-- Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

General issues related to rare disease treatment.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.